U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Premenstrual Dysphoric Disorder

; ; .

Author Information and Affiliations

Last Update: February 19, 2023.

Continuing Education Activity

Premenstrual symptoms include a constellation of mood, behavioral, and physical indications that occur in a cyclic pattern prior to menstruation and then wane off after the menstrual period in women of reproductive age. Most females have only mild discomfort, and symptoms do not interfere with their personal, social, or professional lives; however, 5% to 8% of women have moderate-to-severe symptoms that can cause significant distress and functional impairment. This activity illustrates the presentation of premenstrual dysphoric disorder and highlights the role of the interprofessional team in its management.


  • Review the pathophysiology of premenstrual dysphoric disorder.
  • Describe the presentation of premenstrual dysphoric disorder.
  • Summarize the treatment of premenstrual dysphoric disorder.
  • Explain the means to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by premenstrual dysphoric disorder.
Access free multiple choice questions on this topic.


Premenstrual symptoms include a constellation of mood, behavioral, and physical indications that occur in a cyclic pattern prior to menstruation and then wane off after the menstrual period in women of reproductive age. Most females have only mild discomfort, and symptoms do not interfere with their personal, social, or professional lives; however, 5% to 8% of women have moderate-to-severe symptoms that can cause significant distress and functional impairment.[1] 

Although premenstrual symptoms have been recognized for a long time, the diagnostic criteria have been specified only recently. The nomenclature for premenstrual disorders has changed significantly over the years, evolving from "menses moodiness" in the 18th century to "premenstrual tension" in the early part of the 19th century to finally, "premenstrual syndrome" in the 1950s. While some discomfort prior to menses is quite common, premenstrual syndrome (PMS) includes the subset of women who experience symptoms that are severe enough to impact daily activities and functioning. Late luteal dysphoric disorder (LLDD), now known as premenstrual dysphoric disorder (PMDD), accounts for the most severe form of PMS with the greatest impairment of women’s functioning and perceived quality of life, often prompting them to seek treatment. Anyone who has ovaries can have PMDD, including transgender individuals.

Currently, PMDD is listed in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) as a separate entity under Depressive disorders, with the criteria for diagnosis as follows:

Criterion A - At least 5 of the following 11 symptoms (including at least 1 of the first 4 listed) should be present:

  1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts
  2. Marked anxiety, tension, feelings of being “keyed up” or “on edge”
  3. Marked affective lability
  4. Persistent and marked anger or irritability or increased interpersonal conflicts
  5. Decreased interest in usual activities (eg, work, school, friends, and hobbies)
  6. Subjective sense of difficulty in concentrating
  7. Lethargy, easy fatigability, or marked lack of energy
  8. Marked change in appetite, overeating, or specific food cravings
  9. Hypersomnia or insomnia
  10. A subjective sense of being overwhelmed or out of control
  11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of bloating, or weight gain.

Criterion B symptoms severe enough to interfere significantly with social, occupational, sexual, or scholastic functioning.

Criterion C symptoms discretely related to the menstrual cycle and must not merely represent an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although the symptoms may be superimposed on those of these disorders).

Criterion D - criteria A, B, and C are confirmed by prospective daily ratings during at least 2 consecutive symptomatic menstrual cycles. The diagnosis may be made provisionally before this confirmation.

Women with moderate-to-severe PMS or PMDD experience more quality-of-life detriments and work-productivity losses and incur greater healthcare costs than women with no or only mild symptoms.[2]


The exact etiology of PMS/PMDD is not known. There are, however, risk factors associated with the development of PMS/PMDD, some of which are well-established while others are speculative.

Proven Risk Factors

  • Past traumatic events: Traumatic events and preexisting anxiety disorders are risk factors for the development of PMDD. The underlying mechanisms are unknown, making further investigation necessary.[3]
  • Cigarette smoking: There is a strong association of moderate-to-severe forms of PMS with current smoking status compared to non-smokers (relative risk [RR] 2.1). The risk is elevated even for former smokers (RR 1.8), and the risk of incident PMS tends to increase with the quantity of cigarette smoking (RR of 1.93 for 20 pack-years). Further, the risk of PMDD is significantly higher for women who began smoking during adolescence.[4]
  • Obesity: There is a strong linear relationship between BMI at baseline and risk of incident PMS (p003). For each 1 kg/m2 increase, there was a significant associated increase (3%). The risk of PMS rose significantly in women with BMI at or higher than 27.5 compared with women with a BMI of less than 20.0 kg/m2. RR in women with a BMI of 35.0 kg/m2 was 1.66.[5]

Speculative Risk Factor

  • Genetics: Twin studies have implicated heritable factors in the development of PMS/PMDD. Recent studies have provided support for the involvement of the gene that codes for the serotonergic 5HT1A receptor[6] and allelic variants of the estrogen receptor alpha gene (ESR1) in the development of PMS/PMDD.[7]


Premenstrual symptoms can affect all women of reproductive age, ranging from menarche to menopause.[8] Premenstrual symptoms are a common problem for women in the reproductive age group. In the United States, approximately 70 to 90% of women in the reproductive age group report at least some premenstrual discomfort. Approximately one-third of these women have symptoms that are bothersome enough to qualify for the diagnosis of PMS. The most severe form of premenstrual symptom complex, PMDD, has been noted in 3 to 8% of these PMS cases. Transgender individuals can have premenstrual dysphoric disorder. Anyone with ovaries can have symptoms.

In a study by Halbreich et al., women in the U.S. have about 481 menstrual cycles during this lifespan. Taking into account the 22 months for two pregnancies and postpartum periods, many women roughly experience 459 cycles during their childbearing years. Also, US women with PMDD experience an average of 6.4 days of severe symptoms per menstrual cycle[9]; this is approximately equivalent to 8 years of debilitating symptoms throughout the menstrual cycle. Examining the numbers leads one to the certainty that PMS or PMDD can cause distress and functional impairment over a significant duration of a patient's lifetime, making it an important health problem.


Recent evidence from research studies suggests that reproductive hormone release patterns are normal in women with PMS/PMDD, but they have a heightened sensitivity to cyclical variations in levels of reproductive hormones, which predisposes them to experience mood, behavioral, and somatic symptoms.[10] 

Role of Sex Steroids


Many scientists have postulated that PMS/PMDD symptoms develop because of a decline of progesterone in the late luteal phase that causes CNS changes in gamma-aminobutyric acid (GABA) and progesterone metabolites that interact with the GABA-A receptor complex. However, there are other sets of scientists who argue against this hypothesis by stating that many symptoms can begin at ovulation and the early luteal phase before the fall in the level of progesterone. To further corroborate, some studies showed that the hormonal cyclicity was suppressed by treatment with Gonadotropin-releasing hormone, and re-exposure to progesterone reproduced symptoms even when the hormone concentrations were stable. Also, if the above theory of decline in the late luteal phase indicating progesterone as the precipitating factor were to be believed, then administration of progesterone during this phase would have been an effective treatment which is not.[11]


Allopregnanolone is a metabolite of progesterone, and like progesterone, levels of this metabolite also fluctuate during the menstrual cycle. As mentioned, progesterone metabolites interact with the GABA-A receptor complex and allopregnanolone specifically potentiates inhibitory responses to GABA-A receptor agonists. Some studies suggest that women with PMS/PMDD have diminished functional sensitivity of the GABA-A receptor due to deficient allopregnanolone response to stress.[12]


An alternative hypothesis suggests that preovulatory peak in estradiol, postovulatory increase in progesterone, or both trigger symptoms of PMS/PMDD[13]; however, a shortcoming of this theory is its failure to explain why symptoms start with ovulation for some, but in late luteal phase for others. It has also been reported that estrogen is as efficacious as progesterone in provoking PMS-like complaints, and the estrogen component of hormone replacement therapy can amplify progesterone-induced dysphoria.[14] Besides, the administration of estrogen in the luteal phase has been reported to provoke premenstrual symptoms[15], and giving estrogen antagonists in the luteal phase decreases premenstrual mastalgia.[16] 


Transgender men experience improvements in social functioning and reduced anxiety and depression once testosterone therapy is begun.

Role of Central Neurotransmitters


Serotonin is a central neurotransmitter that is well-proven to be involved in mood and behavior regulation. Sex steroids may affect behavior by exerting their effects on serotonergic transmission. Three proofs authenticate this theory. First, premenstrual symptoms are diminished by selective serotonin reuptake inhibitors (SSRIs) and other treatments that boost serotonin levels, like serotonin-releasing agents.[17][18][19] Second, contrary to the first point, a decrease in serotonergic transmission achieved by a tryptophan-free diet[20] or by treatment with a serotonin-receptor antagonist[21] can give rise to PMS/PMDD symptoms. Third, women with PMS/PMDD have atypical serotonergic transmission and a lower density of serotonin transporter receptors than typical women. In addition, they have a higher level of serotonergic responsiveness in the follicular than in the luteal phase, which is different from that observed in women without PMS/PMDD.[22][23][24]

Gamma-aminobutyric acid

GABA is an inhibitory neurotransmitter, and some imaging studies suggest the possible role of GABA in the pathophysiology of PMS/PMDD based on the fact that some progesterone metabolites interact with GABA A receptors [25][26] and that symptomatic women have different responsiveness of this receptor complex as compared to asymptomatic women.[27] Another noteworthy fact is that GABAergic and serotonergic neurons have meaningful interactions, and thus the role of GABA in the pathophysiology of PMS/PMDD is in keeping with the serotonin hypothesis. Additionally, SRIs also strongly influence enzymes involved in creating progesterone metabolites which in turn modulate GABA A receptors.[28][29][30][31]


Glutamate is an excitatory neurotransmitter, and there is a cyclical fluctuation in its levels during the menstrual cycle for all women (symptomatic and asymptomatic), but symptomatic women seem to have an increased sensitivity to these cyclical changes.[32]

Beta Endorphins

Studies have shown that women with PMDD have lower levels of cortisol and beta-endorphins during both the follicular and luteal phases.[33] These observations suggest abnormalities in the hypothalamic-pituitary-gonadal axis in PMDD which is congruent with the findings of HPA-axis dysregulation in mood disorders.[34][35]

History and Physical

Three Heads of PMDD Symptomatology

  1. Mood
  • Feeling sad, depressed, hopeless, worthless
  • Marked mood lability like mood swings; suddenly feeling sad or tearful
  • Increased irritability and or anger; frequent conflicts with family members or at work
  • Increased anxiety or the feeling of being on edge all the time

    2.  Behavioral

  • Lack of energy, fatigability
  • Decreased interest in normal activities
  • Problems with concentration
  • Changes in appetite, either overeating or craving a specific food
  • Changes in sleep pattern, either hypersomnia or insomnia
  • Feeling overwhelmed or out of control

    3.  Somatic

  • Breast swelling or tenderness
  • Joint or muscle aches
  • A sensation of bloating or weight gain
  • Headaches

Symptom Expression Pattern 

The length of time for which the women experience symptoms of PMDD varies from a few days to 2 weeks. For most symptomatic women, symptoms intensify 6 days before and are the most severe 2 days before the menses.[36][37] Of all the symptoms mentioned, anger and irritability are the most distressing and are experienced slightly before the other symptoms.[36]

As discussed, according to DSM-5, symptoms should be directly related to the menstrual cycle and must not merely represent an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although the symptoms may be superimposed on those of these disorders). Prospective daily ratings must confirm symptoms during at least 2 consecutive symptomatic menstrual cycles. However, a provisional diagnosis may be made before this confirmation.


PMDD Assessment Scales

  1. Premenstrual Symptom Screening Tool (PSST): A questionnaire used to diagnose PMDD with 19 items that allow the patient to rate the severity of their symptoms.[38]
  2. Calendar of Premenstrual Experiences (COPE): Includes 22 symptoms grouped into 4 categories: mood reactivity, autonomic/ cognitive, appetitive, and related to fluid retention.[39]
  3. Visual Analogue Scale (VAS): Steiner et al. used this scale in 1999 to rate each of the 4 core symptoms of PMDD: mood swings, irritability, tension, and depression. The scale consisted of a 100 mm vertical line labeled 0 or “no symptom” at the left end and 100 or “severe” at the right.[38]
  4. Daily Record of Severity of Problems (DRSP): This scale consists of 24 items, out of which 21 items are grouped into 11 distinct symptoms and 3 functional impairment items. The items are rated from 1 (not at all) to 6 (extreme).
  5. Patient Reported Outcomes Measurement Information System (PROMIS): Deorte et al. used PROMIS computerized adaptive testing (PROMIS CAT) to detect premenstrual symptoms of depression, anxiety, and fatigue; the results of the study provided encouraging evidence for the utility of PROMIS instruments for the measurement of effective premenstrual symptoms.[40]

Treatment / Management

Treatment modalities for PMDD can be divided into 2 categories:

  1. Non-Pharmacological Methods
  • Exercise: Improves symptoms through elevation of beta-endorphin levels; however, the evidence is not based on randomized controlled trials.
  • Dietary modifications: Increased intake of complex carbohydrates or proteins ("slow-burning fuels") is believed to increase tryptophan availability, leading to increased serotonin levels. Randomized controlled trials have demonstrated the superiority of calcium in improving emotional and physical symptoms over placebo. Meta-analysis has demonstrated some benefits of vitamin B6 over placebo. Chaster-berry/Vitex agnus-castus also has been shown to be somewhat efficacious by exerting some dopaminergic effect.
  • Stress management: Relaxation/ meditation/ yoga/ breathing techniques.

     2. Pharmacological Methods

  • Psychotropic agents
    • Serotonin Reuptake Inhibitors (SRIs): SRIs have been proven to be effective in the treatment of severe mood and somatic symptoms of PMDD. The ones that have been particularly linked with the relief of symptoms are Clomipramine (a tricyclic antidepressant),[41][42][41] Selective serotonin reuptake inhibitors like citalopram,[43][44] escitalopram, fluoxetine, paroxetine and sertraline, and noradrenaline reuptake inhibitor venlafaxine. Antidepressants that predominantly affect noradrenergic transmission are not as effective for PMDD as SRIs, which means that the effect of SRIs in PMDD is not just an antidepressant effect.[45][46] This is supported by the fact that the beneficial effect of SRIs begins rapidly in PMDD, whereas antidepressant effect takes several weeks. Thus, clinicians can use SRIs intermittently from mid-cycle to menses to treat symptoms of PMDD as opposed to continuous treatment[47]. Side effects of SRIs are usually mild. Nausea is the most common adverse effect, but it usually wears off in a couple of days after starting the therapy and doesn’t reappear even if the therapy is intermittent. Reduced libido and anorgasmia are other common adverse effects, but they are absent in drug-free intervals.
    • Benzodiazepines (BZDs): BZDs like alprazolam have been found to be effective only in women with severe anxiety and premenstrual insomnia. However, since there is a risk of dependence, careful monitoring is required, especially in cases with reported prior substance abuse.[48][49]
  • Suppression of Ovulation
    • Hormonal therapies: For very severe symptoms, clinicians can use hormonal therapies to provide relief. The aim of hormonal therapy is to inhibit the hypothalamic-gonadal cycle; however, this causes medical menopause and leads to hot flashes and an increased risk of osteoporosis. Thus, to prevent these adverse effects, patients are also started back on estrogen and gestagen (a hormone with progesterone-like activity). Some patient reports suggesting recurrence of symptoms with the add-back gestagen therapy. Hence, as an alternative, clinicians can combine GnRH agonist with tibolone (a synthetic steroid with weak estrogenic, progestogenic, and androgenic activity).
    • Danazol: This is a synthetic partial androgen agonist/ antagonist and gonadotropin inhibitor that has also been shown to be efficacious in treating PMDD by inhibiting ovulation. However, it is associated with hirsutism and teratogenicity and thus not preferred as an initial agent.
    • Oral contraceptive pills (OCPs): Although widely used in clinical practice, their efficacy in treating PMDD has not been strongly supported by evidence. Women on OCP experience more hormone-related symptoms on hormone-free days, and hence OCP treatment with fewer hormone-free days might be beneficial to these women. Drospirenone (a gestagen) was particularly found to be effective in treating PMDD symptoms because of its anti-aldosterone and anti-androgenic effects.

Differential Diagnosis

The symptoms of PMDD can overlap with other psychiatric disorders, most importantly major depression, and it is imperative to rule out another existing disorder before making the diagnosis of PMS/PMDD. The key factor in making the diagnosis is the temporal association of symptoms with the menstrual cycle. Some common differentials include:

  1. Major depressive disorder: Depression symptoms include low mood, low energy, anhedonia, appetite change, sleep disturbance, difficulty concentrating, and thoughts of suicide. Roughly half the cases of PMS/PMDD can have a coexisting diagnosis of depression.[50] A diagnosis of PMS or PMDD may predate a diagnosis of depression or depression and PMDD may coexist. Criteria for the diagnosis of these disorders are different but not exclusive.
  2. Thyroid disease (hyperthyroid or hypothyroid):
    • Hypothyroid symptoms and signs include weight gain, constipation, cold intolerance, depression, dry skin, and delayed deep tendon reflexes.
    • Hyperthyroid signs and symptoms include weight loss, poor sleep, heat intolerance, heart rhythm disturbance such as atrial fibrillation, and hyperreflexia.
  3. Generalized anxiety disorder Symptoms of anxiety include palpitations and feelings of fear. Triggers may be identified for anxiety attacks, and the patient shows avoidance of these triggers. Chronic or situational anxiety does not vary with the menstrual cycle. Generalized anxiety disorder and PMDD may coexist. Criteria are different but not exclusive.
  4. Mastalgia: Symptoms of mastalgia may be limited to just breast tenderness and swelling, and mastalgia may be present at times other than during the luteal phase but worsen during the luteal phase.

Enhancing Healthcare Team Outcomes

Premenstrual dysphoric disorder is a well-recognized, severe form of PMS. It is imperative to establish a precise diagnosis of PMDD that is guided by the DSM-5 criteria. While the diagnosis of PMS is fairly common in females of reproductive age, the referring practitioner plays a pivotal role not only in distinguishing PMDD from PMS but also in separating it from other psychiatric disorders like anxiety or depression. Good coordination between the primary physician, gynecologist, and psychiatrist is extremely important in the interprofessional management of these patients.[1] Educating the patients about the symptoms and encouraging them to maintain a diary for an accurate record of symptoms should be emphasized by each of the treating physicians. It is worthwhile to have a therapist on board, too, who can help the patients by teaching them various coping skills to deal with the symptoms of anxiety and depression in addition to medication management.

Review Questions


Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 05;371(9619):1200-10. [PMC free article: PMC3118460] [PubMed: 18395582]
Borenstein JE, Dean BB, Leifke E, Korner P, Yonkers KA. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt). 2007 Oct;16(8):1139-44. [PubMed: 17937566]
Wittchen HU, Perkonigg A, Pfister H. Trauma and PTSD - an overlooked pathogenic pathway for premenstrual dysphoric disorder? Arch Womens Ment Health. 2003 Nov;6(4):293-7. [PubMed: 14628182]
Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Cigarette smoking and the development of premenstrual syndrome. Am J Epidemiol. 2008 Oct 15;168(8):938-45. [PMC free article: PMC2727205] [PubMed: 18701443]
Bertone-Johnson ER, Hankinson SE, Willett WC, Johnson SR, Manson JE. Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt). 2010 Nov;19(11):1955-62. [PMC free article: PMC2971655] [PubMed: 20874240]
Dhingra V, Magnay JL, O'Brien PM, Chapman G, Fryer AA, Ismail KM. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol. 2007 Oct;110(4):788-92. [PubMed: 17906010]
Huo L, Straub RE, Roca C, Schmidt PJ, Shi K, Vakkalanka R, Weinberger DR, Rubinow DR. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry. 2007 Oct 15;62(8):925-33. [PMC free article: PMC2762203] [PubMed: 17599809]
Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:1-23. [PubMed: 12892987]
Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med. 1999 Oct;8(8):1043-52. [PubMed: 10565662]
Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:55-99. [PubMed: 12892990]
Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001 Oct 06;323(7316):776-80. [PMC free article: PMC57352] [PubMed: 11588078]
Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37. [PMC free article: PMC3098121] [PubMed: 19373620]
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16. [PubMed: 9435325]
Björn I, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström G, Bäckström T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab. 2003 May;88(5):2026-30. [PubMed: 12727949]
Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology. 1990;15(5-6):489-93. [PubMed: 1966304]
Oksa S, Luukkaala T, Mäenpää J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG. 2006 Jun;113(6):713-8. [PubMed: 16709215]
Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol. 1990 Aug;76(2):296-301. [PubMed: 2371034]
Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab. 1997 Apr;82(4):1220-8. [PubMed: 9100599]
Steinberg S, Annable L, Young SN, Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry. 1999 Feb 01;45(3):313-20. [PubMed: 10023508]
Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord. 1994 Sep;32(1):37-44. [PubMed: 7798465]
Roca CA, Schmidt PJ, Smith MJ, Danaceau MA, Murphy DL, Rubinow DR. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry. 2002 Nov;159(11):1876-81. [PubMed: 12411222]
Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med. 1991 May;21(2):305-12. [PubMed: 1876635]
Eriksson O, Wall A, Marteinsdottir I, Agren H, Hartvig P, Blomqvist G, Långström B, Naessén T. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res. 2006 Mar 31;146(2):107-16. [PubMed: 16515859]
Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med. 1993;23(1):1-27. [PubMed: 8514462]
Smith SS, Ruderman Y, Frye C, Homanics G, Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl). 2006 Jun;186(3):323-33. [PMC free article: PMC2887339] [PubMed: 16193334]
Sundström Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health. 2003 Feb;6(1):23-41. [PubMed: 12715262]
Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology. 1997 Jan;22(1):25-38. [PubMed: 9141149]
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry. 2004 Feb;161(2):368-70. [PubMed: 14754790]
Sundström I, Bäckström T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology. 1998 Jan;23(1):73-88. [PubMed: 9618754]
Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl). 2006 Jun;186(3):362-72. [PubMed: 16432684]
Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A. 1999 Nov 09;96(23):13512-7. [PMC free article: PMC23979] [PubMed: 10557352]
Batra NA, Seres-Mailo J, Hanstock C, Seres P, Khudabux J, Bellavance F, Baker G, Allen P, Tibbo P, Hui E, Le Melledo JM. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry. 2008 Jun 15;63(12):1178-84. [PubMed: 18061146]
Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol. 2002 Jul;21(4):358-67. [PubMed: 12090678]
Joffe H, Kim DR, Foris JM, Baldassano CF, Gyulai L, Hwang CH, McLaughlin WL, Sachs GS, Thase ME, Harlow BL, Cohen LS. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. J Clin Psychiatry. 2006 Feb;67(2):297-304. [PubMed: 16566627]
Young EA, Korszun A. The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinol Metab Clin North Am. 2002 Mar;31(1):63-78. [PubMed: 12055991]
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr;85(3):275-82. [PubMed: 15780697]
Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry Res. 2005 Mar 30;134(1):27-36. [PubMed: 15808287]
Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003 Aug;6(3):203-9. [PubMed: 12920618]
Feuerstein M, Shaw WS. Measurement properties of the calendar of premenstrual experience in patients with premenstrual syndrome. J Reprod Med. 2002 Apr;47(4):279-89. [PubMed: 12012879]
Junghaenel DU, Schneider S, Stone AA, Christodoulou C, Broderick JE. Ecological validity and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) instruments for detecting premenstrual symptoms of depression, anger, and fatigue. J Psychosom Res. 2014 Apr;76(4):300-6. [PMC free article: PMC4162640] [PubMed: 24630180]
Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993 Sep;9(2):133-45. [PubMed: 8216696]
Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992 Jan;85(1):39-47. [PubMed: 1546547]
Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998 Oct;18(5):390-8. [PubMed: 9790157]
Ravindran LN, Woods SA, Steiner M, Ravindran AV. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health. 2007;10(3):125-7. [PubMed: 17431739]
Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997 Aug;17(4):261-6. [PubMed: 9241004]
Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999 Oct;56(10):932-9. [PubMed: 10530636]
Sundblad C, Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol. 1997 Aug;7(3):201-6. [PubMed: 9213079]
Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987 Jul;70(1):37-43. [PubMed: 3299178]
Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990 Mar;47(3):270-5. [PubMed: 2407209]
Beck LE, Gevirtz R, Mortola JF. The predictive role of psychosocial stress on symptom severity in premenstrual syndrome. Psychosom Med. 1990 Sep-Oct;52(5):536-43. [PubMed: 2247559]

Disclosure: Sanskriti Mishra declares no relevant financial relationships with ineligible companies.

Disclosure: Harold Elliott declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.

Copyright © 2023, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK532307PMID: 30335340


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...